Insider Transactions in Q4 2022 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-1.04%
|
$250,000
$20.32 P/Share
|
|
Dec 20
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.49%
|
$200,000
$20.07 P/Share
|
|
Dec 12
2022
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
600,854
-9.09%
|
-
|
|
Dec 08
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
4,358
-1.06%
|
$95,876
$22.08 P/Share
|
|
Dec 02
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.21%
|
$105,000
$21.55 P/Share
|
|
Dec 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.39%
|
$210,000
$21.77 P/Share
|
|
Dec 01
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-0.6%
|
$110,000
$22.03 P/Share
|
|
Nov 21
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-0.51%
|
$262,500
$21.06 P/Share
|
|
Nov 21
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-1.69%
|
$210,000
$21.07 P/Share
|
|
Nov 16
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,513
-0.12%
|
$31,773
$21.46 P/Share
|
|
Nov 16
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
377
-0.03%
|
$7,917
$21.46 P/Share
|
|
Nov 16
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
430
-0.14%
|
$9,030
$21.46 P/Share
|
|
Nov 15
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,562
+0.29%
|
-
|
|
Nov 15
2022
|
Samuel C. Blackman HEAD OF R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
1,187
+0.09%
|
-
|
|
Nov 15
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
1,375
+0.46%
|
-
|
|
Nov 02
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.18%
|
$100,000
$20.01 P/Share
|
|
Nov 01
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-1.02%
|
$250,000
$20.03 P/Share
|
|
Nov 01
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$200,000
$20.0 P/Share
|
|
Nov 01
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.16%
|
$100,000
$20.04 P/Share
|
|
Nov 01
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.29%
|
$200,000
$20.03 P/Share
|
|
Oct 04
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.15%
|
$100,000
$20.0 P/Share
|
|
Oct 03
2022
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
10,000
-3.18%
|
$200,000
$20.05 P/Share
|
|
Oct 03
2022
|
Papanek Julie Grant Director |
SELL
Open market or private sale
|
Indirect |
5,000
-1.14%
|
$100,000
$20.06 P/Share
|
|
Oct 03
2022
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.78%
|
$190,000
$19.99 P/Share
|
|
Oct 03
2022
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-1.01%
|
$250,000
$20.05 P/Share
|